GLP-1RAs are a class of incretin-based therapies for the management of hyperglycemia and are also among the most effective drugs for the treatment of obesity.[3,4,10,11] These agents interact with various physiological mechanisms involved in T2D by boosting insulin production and curbing glucagon to regulate blood glucose levels. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.